LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

66.34 3.48

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

63.6

Max

66.77

Belangrijke statistieken
By Trading Economics
Inkomsten	-317M -142M
Verkoop	98M 452M
K/W Sectorgemiddelde	25.027 49.8
Winstmarge	-31.342
Werknemers	423
EBITDA	-3.5M 281M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+40.99% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.7B 7.6B
Vorige openingsprijs	62.86
Vorige sluitingsprijs	66.34

Nieuwssentiment

By Acuity

50%

175 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

60.49 / 70.14 Steun & Weerstand

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mei 2026, 22:15 UTC

Acquisities, Fusies, Overnames

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mei 2026, 23:46 UTC

Marktinformatie

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mei 2026, 23:33 UTC

Marktinformatie

Gold Rises on Possible Position Adjustments -- Market Talk

11 mei 2026, 22:37 UTC

Marktinformatie

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mei 2026, 22:32 UTC

Winsten

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mei 2026, 22:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mei 2026, 21:49 UTC

Winsten

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mei 2026, 21:42 UTC

Marktinformatie

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mei 2026, 21:23 UTC

Acquisities, Fusies, Overnames

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mei 2026, 21:12 UTC

Winsten

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mei 2026, 21:12 UTC

Winsten

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

11 mei 2026, 20:44 UTC

Winsten

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mei 2026, 20:43 UTC

Winsten

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Rev $136.4M >CLSK

11 mei 2026, 20:30 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Cont Ops EPS $2.24 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Rev $1.6B >STE

11 mei 2026, 20:30 UTC

Winsten

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Adj EPS $2.83 >STE

11 mei 2026, 20:22 UTC

Populaire aandelen

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mei 2026, 19:37 UTC

Winsten

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mei 2026, 19:32 UTC

Marktinformatie

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

40.99% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 90.4 USD 40.99%

Hoogste 96 USD

Laagste 75 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

175 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.